All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

The distribution of methicillin-sensitive (MSSA) and methicillin-resistant *S*. *aureus* (MRSA) bacteremia varies substantially by geographical region \[[@pone.0170236.ref001]\] \[[@pone.0170236.ref002]\] \[[@pone.0170236.ref003]\] \[[@pone.0170236.ref004]\] \[[@pone.0170236.ref005]\]. *Staphylococcus aureus*, however, remains a leading cause of community- and healthcare-associated bacteremia worldwide \[[@pone.0170236.ref003]\] \[[@pone.0170236.ref005]\]. Despite efforts to reduce its incidence, *S*. *aureus* bacteremia (SAB) remains frequent and associated with mortality rates up to 25% \[[@pone.0170236.ref003]\]. SAB acquisition and outcome are affected by patients' comorbidities, infection site, and methicillin-resistance \[[@pone.0170236.ref006]\] \[[@pone.0170236.ref007]\]. In this patient population, evidence-based bundle interventions demonstrated to have a positive impact in clinical management and outcome \[[@pone.0170236.ref008]\]. In particular, results from a recent metanalysis suggested that infectious diseases (ID) consultation might improve clinical care and impact hospital survival in patients with SAB \[[@pone.0170236.ref008]\]. Most of the studies, however, focused on predictors of 30- and 60 day-mortality even if high early (≤ 7 day) mortality rates have been reported among patients with SAB \[[@pone.0170236.ref006]\] \[[@pone.0170236.ref007]\] \[[@pone.0170236.ref008]\] \[[@pone.0170236.ref009]\] \[[@pone.0170236.ref010], [@pone.0170236.ref011]\] \[[@pone.0170236.ref012]\].Aim of the study was to describe the epidemiology and clinical characteristics of patients with SAB and assess the prognostic factors for early (7-day) and late (30-day) mortality.

Material and Methods {#sec002}
====================

Study design, setting and patients {#sec003}
----------------------------------

A retrospective, observational, cohort study was performed in two tertiary care university hospitals in Italy that admit approximately 90,000 patients per year. All episodes of clinically significant SAB in adult patients (aged 18 years and older) between January 2011 and December 2014 were included. Patients were followed in the participant centers until discharge or death. Cases were detected through electronic databases, using a standardized protocol including age, sex, comorbidities, source of infection, setting of acquisition, antimicrobial susceptibility, antibiotic treatment, and clinical outcome. This study was approved by the local institutional review board (Comitato Etico Regionale Unico). Because of the retrospective nature of the study, the requirement for informed consent was waived.

Definitions {#sec004}
-----------

SAB was defined as the presence of ≥1 positive blood culture for *S*. *aureus* in patients with signs and symptoms consistent with an infection \[[@pone.0170236.ref007]\]. Onset of SAB was defined as the date of collection of the first blood culture yielding positivity for *S*.*aureus*. Only the first clinically significant episode of infection with SAB for each patient was included in the analysis.

SAB was defined as hospital-acquired (HA) if the first positive blood culture was performed more than 48 hours after admission either to the intensive care unit (ICU) or to another hospital ward \[[@pone.0170236.ref013]\]. Other SAB were classified as HCA or CA according to previously reported definitions \[[@pone.0170236.ref014]\].

In the presence of a laboratory-confirmed bloodstream infection, bacteremia of unknown source or primary bacteremia was defined when its origin could not been established after careful examination of clinical signs, microbiological findings, and imaging results. Otherwise, 72 hours from blood culture collection or by the presence of an ID physician responsible for the patient's management. At both hospitals, ID service consultation was available and optional.

Empirical therapy was defined as adequate when at least one active antimicrobial agent was administered at recommended doses according to susceptibility data within the first 48 hours after the blood cultures were performed. Antibiotic de-escalation was defined as switch to a narrower spectrum agent \[[@pone.0170236.ref015]\]. Targeted antibiotic therapy was considered adequate when at least one active antimicrobial agent was administered, according to susceptibility data, at recommended doses after 96 hours following blood cultures collection. Regimens were classified as monotherapy or combination therapy depending on the number of active drugs included. Overall mortality was determined at 7 days (early mortality) and at 30 days (late mortality) after the first blood culture.

Blood cultures and microbiology analysis {#sec005}
----------------------------------------

Identification of isolates and antimicrobial susceptibility profiles were obtained through VITEK 2 (bioMérieux Inc., Hazelwood, MO, USA). The Aris Sensititre instrument for incubating and reading susceptibility plates (Trek Diagnostic Systems Inc., Independence, OH) was used according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints, and Etest strips (BioMerieux) were used to confirm antibiotic resistance \[[@pone.0170236.ref016]\]

Statistical analysis {#sec006}
--------------------

Continuous and categorical data were reported as median, 25th and 75th percentile and frequency distributions, respectively. The Wilcoxon test was used to determine if differences existed between groups for continuous variables, respectively. Categorical variables were evaluated using chi-square or, when appropriate, the two-tailed Fisher's exact test. Multiple logistic regression analysis was performed to identify risk factors that were associated with 7- and 30-day hospital mortality \[JMP, SAS, NC, USA). Covariates that were significant at 0.10 in the univariate analysis and therapy-related variables were further evaluated for inclusion in multivariable regression models, using a backward stepwise algorithm. Given the high number of potential independent variables, a backward stepwise algorithm was used to identify the best-fitting subset of variables for use in the final multivariable regression model. In particular, Akaike's Information Criterion (AIC) was used to assess the models' fit and the model with the lowest AIC was selected for the multivariable analysis. All tests were two-tailed, and a P value less than 0.05 was determined to represent statistical significance.

Results and Discussion {#sec007}
======================

Population characteristics {#sec008}
--------------------------

During the four-year study period, 337 episodes of SAB were diagnosed (see the database in [S1](#pone.0170236.s001){ref-type="supplementary-material"} and [S2](#pone.0170236.s002){ref-type="supplementary-material"} Data). The demographic characteristics and underlying conditions of these patients are summarised in [Table 1](#pone.0170236.t001){ref-type="table"}.

10.1371/journal.pone.0170236.t001

###### Characteristics of patients with staphylococcal bacteremia caused by MRSA compared with patients with staphylococcal bacteremia caused by MSSA.

![](pone.0170236.t001){#pone.0170236.t001g}

                                                              MRSAn = 132(39.2%)   MSSAn = 205 (60.9%)   P-value
  ----------------------------------------------------------- -------------------- --------------------- ---------
  **Characteristic**                                                                                     
  **Demographic data**                                                                                   
  Age, years (median, IQR)                                    69 (56--77)          68 (58--79)           0.88
  Gender, male                                                92/132 (69.7)        127/205 (62)          0.15
  BMI (kg/m^2^) (median, IQR)                                 24.6 (22.2--28.7)    24.5 (22.5--27.6)     0.76
  **Baseline disease**                                                                                   
  AAC score (median, IQR)                                     6 (2--6)             5 (2--7)              0.52
  Solid organ recipient                                       3/132 (2.3)          10/205 (4.9)          0.23
  Solid cancer                                                34/132 (25.8)        45/205 (22)           0.42
  Hematologic malignancies                                    3/132 (2.3)          21/205 (10.2)         0.006
  Neutropenia (\<500 PMN/mm3)                                 9/132 (6.8)          10/205 (4.9)          0.45
  *Dialysis*                                                  17/132 (12.9)        21/205 (10.2)         0.46
  Cr clearance (ml/min) (median, IQR)                         90.4 (39.2--133.1)   92.8 (52.2--136.6)    0.88
  Diabetes                                                    42/132 (31.8)        73/205 (35.6)         0.47
  Cirrhosis                                                   18/132(13.6)         35/205(17.1)          0.40
  Child score \[[@pone.0170236.ref032]\]                                                                 
  A                                                           1/6 (16.7)           5/19 (26.3)           0.64
  B                                                           1/6 (16.7)           3/19 (15.8)           0.96
  C                                                           4/6 (66.6)           11/19 (57.9)          0.71
  **Baseline treatment**                                                                                 
  Immunosuppressive therapy                                   11/132 (8.3)         12/205 (5.9)          0.38
  Steroids therapy                                            18/132 (13.6)        32/205 (15.6)         0.62
  Cancer chemotherapy (\<30 days)                             10/132 (7.6)         21/205 (10.2)         0.41
  **Other risk factors**                                                                                 
  Active consumption of drugs intravenously                   9/132 (6.8)          10/205 84.9)          0.45
  CVC (\>72h)                                                 70/132 (53)          73/205 (35.6)         0.002
  Other intravascular device (\>72h)                          10/132 (7.6)         5/205 (2.4)           0.03
  Abdominal drainage catheter                                 15/132 (11.4)        9/205 (4.4)           0.02
  Urinary catheter (\>72h)                                    54/132 (40.9)        64/205 (31.2)         0.07
  Recent antimicrobial therapy (\<30 days)                    60/132 (45.5)        63/205 (30.7)         0.006
  Surgery (\<30days)                                          34/132 (25.8)        30/205 (14.6)         0.01
  Prior ICU care (\<90 days)                                  17/132 (12.9)        14/205 (6.8)          0.06
  **SAB data**                                                                                           
  **Setting of acquisition**                                                                             
  Community acquired                                          2/132 (1.5)          29/205 (14.2)         \<0.001
  Health care associated                                      40/132 (30.3)        53/205 (25.8)         0.37
  Hospital acquired                                           90/132 (68.2)        123/205 (60)          0.13
  **Source of infection**                                                                                
  Unknown                                                     38/132 (28.8)        106/205 (51.7)        \<0.001
  CVC                                                         23/132 (17.4)        16/205 (7.8)          0.007
  Pulmonary                                                   13/132 (9.9)         7/205 (3.4)           0.02
  Endocarditis                                                23/132(17.4)         14/205(6.8)           0.002
  Skin soft tissues                                           15/132 (11.4)        27/205 (13.2)         0.61
  Bone                                                        1/132 (0.8)          7/205 (3.4)           0.12
  Surgical site                                               8/132 (6.1)          10/205 (4.9)          0.65
  Urinary                                                     5/132 (3.8)          8/205 (3.9)           0.95
  Other                                                       6/132 (4.5)          10/205 (4.9)          0.88
  **Clinical presentation**                                                                              
  Septic shock                                                25(18.9%)            20(9.8)               0.03
  ICU admission \<72h                                         10/132 (7.6)         11/205 (5.4)          0.41
  **Therapeutic management**                                                                             
  Infectious disease consultation                             57/132 (43.2)        117/204 (57.4)        0.01
  CVC removal in patients with CVC \>72h                      54/70 (77.1)         57/73 (78.1)          0.89
  Source control in patients with known source of infection   34/94 (36.2)         40/99 (40.4)          0.54
  Empiric or targeted antimicrobial therapy                   126/132 (95.5)       205/205 (100)         0.002
  Empiric antimicrobial therapy                               116/132 (87.9)       190/205 (92.7)        0.14
  Empiric Daptomycin                                          7/132 (5.3)          25/205 (12.2)         0.04
  Empiric Glycopeptide                                        25/132 (18.9)        25/205 (12.2)         0.09
  Targeted antimicrobial therapy                              124/132 (93.9)       197/205 (96.1)        0.36
  De-escalation                                               35/130 (26.9)        75/203 (37)           0.06
  Start of therapy/de-escalation (days) (median, IQR)         5 (3--10)            5 (3--7)              0.84
  Adequate initial (\< 48 h) therapy                          32/132 (24.2)        189/205 (92.2)        \<0.001
  If adequate initial therapy, combination therapy            10/32 (31.3)         85/189 (45)           0.15
  Adequate targeted (\> 96 h) therapy                         120/132 (90.9)       204/205 (99.5)        \<0.001
  Duration of therapy (days) (median, IQR)                    16 (8--22)           17 (14--29)           0.008
  Duration of hospitalization (days) (median, IQR)            32 (20--53)          28 (14.5--47.5)       0.18

Data are no. of positive results / total number studied (%), unless otherwise indicated.

AAC, age adjusted Charlson; BMI, body mass index; Cr, creatinine; CVC, central venous catheter; ICU, intensive care unit; IQR, interquartile range; y, years; MRSA, methicillin resistant S*taphylococcus aureus*; SAB, *Staphylococcus aureus* bacteremia.

Of all cases of SAB, 9.2% were CA, 27.6% HCA and 63.2% were nosocomial. Among nosocomial infections, the majority was acquired in a medical ward (63.9%). Most common sites of infection were skin and soft tissue (12.5%), CVC-related infections (11.6%), endocarditis (10.9%), respiratory tract infections (5.9%), surgical site (5.3%), urinary tract (3.9%) and bone infections (2.4%). In 144 (42.7%) patients a clear source of infection was not identified.

Antimicrobial resistance and therapeutic management {#sec009}
---------------------------------------------------

MRSA isolates were identified in 132/337 cases (39.2%), mostly among HCA (43%, 40/93) and HA (42.3%, 90/213) ([Table 1](#pone.0170236.t001){ref-type="table"}). MRSA isolates were more common among patients with indwelling devices (e.g., CVC and abdominal drainage catheter), recent surgery, and antimicrobial therapy compared to MSSA ([Table 1](#pone.0170236.t001){ref-type="table"}). Patients with MRSA bacteremia had higher severity at presentation (e.g., septic shock) and greater proportion of pulmonary and CVC-related infections compared to MSSA bacteremia. Adequate empiric and definitive antibiotic therapy, as well as use of empiric daptomycin, were lower in patients with MRSA isolates compared to MSSA isolates. The comparison between patients with MRSA and MSSA SAB is reported in [Table 1](#pone.0170236.t001){ref-type="table"}.

An ID specialist was consulted in 51.6% of cases within 72 hours of the onset of bacteremia. Once the diagnosis of SAB was suspected, 90.8% (306/337) of patients received empiric systemic antibiotic therapy. An empiric combination therapy was prescribed in 37.9% (116/306). A beta-lactam represented the most used empiric regimen (189/306, 61.8%), followed by glycopeptides (53/306, 17.3%) and fluoroquinolones (40/306, 13.1%). Empirical therapy was considered adequate in 219 (64.9%) episodes, and in 43.3% of cases included a combination treatment. Overall, definitive antibiotic therapy was appropriate in 96.4% (325/337).

Outcome {#sec010}
-------

Twenty-one patients (6.2%) were admitted to the ICUs ≤ 72 hours after the first positive blood culture. Seven- and 30-day mortality were 13.1% (44 out of 337) and 25.5% (86 out of 337), respectively, and were significantly higher for patients with MRSA infections compared to MSSA infections at both time-periods ([Table 2](#pone.0170236.t002){ref-type="table"}). Compared to survivors, patients with SAB who died within 7 or 30 days after first positive blood culture were more likely to be older, have a higher age-adjusted Charlson score, have a pulmonary or cardiac source of infection, present with septic shock, and be admitted to the ICU within 72 hours from SAB diagnosis. In contrast, mortality was lower in patients with a urinary tract source of infection and undergoing catheter removal. Lower mortality rates were also reported in patients receiving adequate therapy, patients treated with daptomycin or undergoing de-escalation therapy, and those evaluated by an ID specialist. Risk factors for mortality at univariate analysis of are shown in [Table 2](#pone.0170236.t002){ref-type="table"}.

10.1371/journal.pone.0170236.t002

###### Univariate analysis of risk factors for mortality at 7 and 30 days in patients with *Staphylococcus aureus* bacteremia.

![](pone.0170236.t002){#pone.0170236.t002g}

                                                        7-day               30-day                                                                 
  ----------------------------------------------------- ------------------- -------------------- --------- ------------------- ------------------- ---------
  Age, years (median, IQR)                              68 (57--77)         75 (60--79)          0.03      68 (56--76.3)       74 (59--82)         0.003
  Gender, male                                          193 (65.8)          26 (59.1)            0.36      164 (65.3)          55 (64)             0.8
  BMI (kg/m^2^) (median, IQR)                           24.6 (22.5--27.8)   24.6 (21.9--27.4)    0.7       24.6 (22.5--28.1)   24.6 (21.7--26.3)   0.26
  AAC score (median, IQR)                               5 (2--6)            6 (4--8)             0.01      5 (2--6)            6 (4--8)            \<0.001
  Solid organ recipient                                 12 (4.1)            1 (2.3)              1.00      13 (5.1)            1(1.2)              0.2
  Solid cancer                                          64 (21.8)           14(31.8)             0.15      56 (22.3)           22 (25.6)           0.54
  Hematologic malignancies                              19 (6.5)            5(11.4)              0.24      16 (6.3)            8 (9.3)             0.39
  Neutropenia (\<500 neutrophil count/mm3)              12 (4.1)            7 (15.9)             0.002     13 (5.1)            7 (8.1)             0.26
  Dialysis                                              31 (10.6)           6(13.6)              0.55      29 (11.5)           9 (10.5)            0.82
  Cr clearance (ml/min) (median, IQR)                   93.3 (51.8--136)    61.4 (29.5--109.9)   0.21      97 (57--138)        63 (29--105)        0.03
  Diabetes                                              104 (35.5)          10 (22.7)            0.09      81 (32.2)           33 (38.4)           0.29
  Cirrhosis                                             49 (16.7)           7(15.9)              0.89      39 (15.5)           15 (17.4)           0.66
  **Child score**                                                                                1\.                                               
  A                                                     11/49 (22.5)        4/7 (57.1)           0.4       13 (33.3)           1 (6.7              0.3
  B                                                     8/49 (16.3)         0                    1.0       10 (25.6)           0 (0)               0.12
  C                                                     30/49 (61.2)        3/7 (42.9)           1.0       16 (41.2)           14 (93.3)           0.02
  Immunosuppressive therapy                             21 (7.2)            2 (4.6)              0.75      21 (8.3)            2 (2.3)             0.05
  Steroid therapy                                       43 (14.7)           7 (15.9)             0.84      36(14.3)            13 (15.1)           0.91
  Cancer chemotherapy (\<30 days)                       27 (9.2)            4 (9.1)              1.00      25 (9.9)            7 (8.1)             0.66
  Active consumption of drugs intravenously             14 (4.8)            5 (11.4)             0.08      13 (5.1)            6/86 (7)            0.56
  CVC (\>72h)                                           124 (42.3)          19 (43.2)            0.91      104 (41.4)          39 (45.4)           0.53
  Other intravascular device (\>72h)                    13 (4.4)            2 (4.6)              1.00      14 (5.5)            1 (1.2)             0.13
  Abdominal drainage catheter                           18 (6.2)            6 (13.6)             0.07      18 (7.1)            6 (7)               0.92
  Urinary catheter (\>72h)                              98 (33.4)           20 (45.5)            0.12      86 (34.2)           33 (38.4)           0.52
  Recent antimicrobial therapy (\<30 days)              101 (34.4)          21 (47.7)            0.09      83 (33.1)           39/86 (45.4)        0.05
  Surgery (\<30days)                                    53 (18.0)           10 (22.7)            0.47      51(20.3)            12/86 (14)          0.17
  Prior ICU care (\<90 days)                            28 (9.6)            3 (6.8)              0.78      22 (8.7)            9/86 (10.5)         0.68
  **Setting of acquisition**                                                                                                                       
  Community acquired                                    25 (8.5)            6 (13.6)             0.30      22 (8.7)            9(10.5              0.6
  Health care associate                                 82 (28.0            11 (25)              0.6       68 (27.1)           24 (27.9)           0.96
  Hospital acquired                                     185(63.5)           27 (61.4)            0.80      156(62.1)           53(61.6)            0.77
  **Source of infection**                                                                                                                          
  Unknown                                               126 (43)            18 (40.9)            0.79      99 (39.4            43 (50)             0.09
  CVC                                                   35 (11.9)           4 (9.1)              0.58      31 (12.3)           8 (9.3)             0.55
  Pulmonary                                             14 (4.8)            6 (13.6)             0.02      9 (3.5)             9 (10.5)            0.02
  Endocarditis                                          24 (8.2             13 (29.6)            \<0.001   22 (8.7)            15(17.4             0.03
  Skin soft tissues                                     40 (13.7)           2 (4.6)              0.1       33 (13.1            9 (10.5             0.4
  Bon                                                   8 (2.7)             0 (0)                0.60      8 (3.1)             0 (0)               0.12
  Surgical site                                         18 (6.1)            0 (0)                0.15      17 (6.8)            1 (12)              0.05
  Urinary                                               13 (4.4             0 (0                 0.23      13 (5.1)            0 (0                0.02
  Other                                                 15 (5.1)            1 (2.3)              0.70      15 (5.9)            1 (1.2)             0.08
  MRSA                                                  101(34.4)           30 (68.2)            \<0.001   83 (33.1)           47 (54.7)           \<0.001
  Septic shock                                          20 (6.8)            23 (52.3)            \<0.001   19(7.5)             24(27.9)            \<0.001
  ICU admission \<72h                                   14(4.8)             7 (15.9)             0.005     10(3.9)             11 (12.8)           0.004
  Infectious disease consultation                       166 (56.7)          8 (18.2)             \<0.001   147 (58.6)          27 (31.4)           \<0.001
  CVC removal in patients with CVC \>72h                102/124 (82.2)      9/19 (47.3)          0.002     89/104 (85.6)       24/39(61.5)         0.002
  Source control                                        68/167 (40.7)       6/26 (23.1)          0.09      60/152 (39.5)       14/43 (32.6)        0.41
  Empiric antimicrobial therapy                         267 (91.1)          39 (88.6)            0.54      228 (90.8)          78 (90.7)           0.92
  Empiric Daptomycin                                    31 (10.6)           1 (2.3)              0.08      29 (11.5)           3 (3.5)             0.02
  Empiric Glycopeptide                                  45 (15.3)           5 (11.3)             0.48      34 (13.5)           16 (18.6)           0.29
  Targeted antimicrobial therapy                        290 (98.9)          31 (70.5)            \<0.001   248 (98.8)          74 (86.1)           \<0.001
  De-escalation therapy                                 105(35.8)           5 (11.6)             0.001     81 (32.2)           27 (31.4)           0.09
  Start of therapy/de-escalation (days) (median, IQR)   5 (3--9)            2 (1.5--5.5)         0.07      5 (3--8)            4.5 (3--8)          0.58
  Adequate therapy (\< 48h)                             201(68.6)           20 (45.5)            0.002     175 (69.7)          46 (53.5)           0.005
  If adequate initial therapy, combination therapy      90/201 (44.8)       5/20 (25)            0.09      79/173 (45.7)       15/46 (32.6)        0.11
  Adequate targeted therapy (\> 96h)                    288(98.2)           36 (81.8)            \<0.001   247 (98.4)          79 (90.7)           0.001

Multivariate analysis identified as risk factors independently associated to both early and late fatal outcome a high age-adjusted Charlson score, the occurrence of endocarditis, septic shock at clinical presentation, and infections caused by MRSA. Other risk factors, only for 30-day mortality, included Child C cirrhosis and primary bacteremia. Consultation with an ID specialist and de-escalation therapy represented factors associated with a decreased risk of mortality at both timepoint and at 7-days, respectively ([Table 3](#pone.0170236.t003){ref-type="table"}). ID consultation was associated to higher rates of adequate initial antibiotic regimen (71.8% vs. 57.6%, P = 0.006) and more frequent recommendation for the use of daptomycin in empiric therapy (53.2% vs. 30.5%, P = 0.001) ([Table 4](#pone.0170236.t004){ref-type="table"}).

10.1371/journal.pone.0170236.t003

###### Multivariate analysis of risk factors for mortality due to *Staphylococcus aureus* bacteremia at 7 and 30 days.

![](pone.0170236.t003){#pone.0170236.t003g}

  Characteristic                    7-day mortality    30-day mortality                     
  --------------------------------- ------------------ ------------------ ----------------- ---------
  AAC score (median, IQR)           1.3 (1.1--1.5)     0.001              1.2 (1.1--1.4)    \<0.001
  Child score C                     NS                 NS                 3.9 (1.1--14.4)   0.04
  **Source of infection**                                                                   
  Unknown                           NS                 NS                 2.5 (1.3--5)      0.007
  Endocarditis                      4.5 (1.4--14.6)    0.01               3.8 (1.4--10.2)   0.009
  MRSA                              3.2 (1.4--8.1)     0.007              2.1 (1.2--3.9)    0.02
  Septic shock                      13.5 (5.4--36.4)   \<0.001            4 (1.7--9.7)      0.01
  Infectious disease consultation   0.1 (0.05--0.4)    \<0.001            0.4 (0.2--0.7)    0.002
  De-escalation therapy             0.3 (0.1--0.7)     0.01               NS                NS

AAC, age-adjusted Charlson score; IQR, interquartile range; MRSA, methicillin resistant S*taphylococcus aureus*.

OR, Odds ratio; NS = non significant.

10.1371/journal.pone.0170236.t004

###### Univariate analysis of SAB with infectious disease consultation VS. SAB without ID consultation.

![](pone.0170236.t004){#pone.0170236.t004g}

  Variables                                            ID consultation n = 174 (51.6%)   Non-ID consultation n = 163 (48.4%)   p-value
  ---------------------------------------------------- --------------------------------- ------------------------------------- ---------
  **Adequate initial (\< 48 h) therapy**               125 (71.8%)                       94/163 (57.6%)                        0.006
  **Empiric therapy with Daptomycin**                  31 (17.8%)                        4/163 (2.5%)                          \<0.001
  **Adequate initial (\< 48 h) combination therapy**   66/124 (53.2%)                    29/95 (30.5%)                         0.001

Abbreviations: ID, infectious disease.

Discussion {#sec011}
==========

The proportion of MRSA has declined in the United States and in some European countries, including Italy, over the past years, but still remains a concern for public health and a major cause of nosocomial infections \[[@pone.0170236.ref001]\] \[[@pone.0170236.ref002]\]. In our study, we observed methicillin-resistance rates of about 40%, slightly higher than 34% reported for Italy by the European Antimicrobial Resistance Surveillance Network in 2014 \[[@pone.0170236.ref001]\]. In our study, MRSA accounted for most nosocomial and healthcare-associated infections but only for a limited proportion of community-acquired infections, stressing the importance of the clinical setting in defining patient populations at risk for MRSA bacteremia \[[@pone.0170236.ref017]\] \[[@pone.0170236.ref018]\]. Previous studies showed higher mortality rates among patients with MRSA bacteremia compared to MSSA, but the results are conflicting \[[@pone.0170236.ref007]\] \[[@pone.0170236.ref012]\] \[[@pone.0170236.ref019]\] \[[@pone.0170236.ref020]\] \[[@pone.0170236.ref021]\]. In our study, methicillin resistance was an independent risk factor for both early and late mortality ~~survival~~. One reason could be represented by higher rates of inadequate treatment associated with MRSA compared to MSSA or by other potential confounding factors (e.g., disease severity, risk factors) associated with MRSA infections \[[@pone.0170236.ref010]\] \[[@pone.0170236.ref020]\] \[[@pone.0170236.ref022]\] \[[@pone.0170236.ref023]\]. Our study, in particular, showed lower rates of appropriate empiric and definitive therapy in patients with MRSA compared to MSSA infections.

We reported a significant survival benefit in SAB when ID service was involved. Specifically, ID consultation impacted long term as well as short-term mortality. ID consultation was also associated with an adequate initial therapy and empiric use of daptomycin. Our data support the growing body of evidence that ID consultation improves patients' outcomes \[[@pone.0170236.ref008]\] \[[@pone.0170236.ref009]\] \[[@pone.0170236.ref024]\]. ID consultation can be optional or mandatory, depending on hospital policies, and its rate can vary from 33 to 88% \[[@pone.0170236.ref024]\] \[[@pone.0170236.ref025]\]. In our cohort, an ID specialist was consulted within 72 hours of the onset of bacteremia in only half of cases. The need to increase ID stewardship as part of hospital bundle interventions to positively impact patient care decisions and reduce SAB mortality should be carefully considered by all hospitals \[[@pone.0170236.ref008]\] \[[@pone.0170236.ref009]\] \[[@pone.0170236.ref011]\].

As previously reported, SAB mortality in our cohort increased with older age and presence of multiple comorbidities, including Child C cirrhosis \[[@pone.0170236.ref006]\] \[[@pone.0170236.ref007]\] \[[@pone.0170236.ref026]\] \[[@pone.0170236.ref027]\] \[[@pone.0170236.ref028]\] \[[@pone.0170236.ref029]\]. Severity at presentation also influenced SAB prognosis, being septic shock an independent risk factor for both early and late mortality \[[@pone.0170236.ref023]\].

We confirmed the occurrence of endocarditis as an independent risk factor for poor outcomes, including early mortality \[[@pone.0170236.ref006]\] \[[@pone.0170236.ref010]\]. Moreover, a relationship between death and the absence of an identified focus emerged for late mortality. In these instances, a better diagnostic definition of the source of infection could help to reach a better source control and improve patients' management \[[@pone.0170236.ref030]\]

De-escalation therapy was also associated with reduced 7-days mortality. A reason could be represented by overall better clinical evolution or absence of multidrug resistance in patients undergoing de-escalation therapy \[[@pone.0170236.ref015]\].

Interestingly, combination therapy (mainly association of beta-lactams and glycopeptides) was often prescribed in our study (40% of all SAB) but did not impact the mortality. A reason could be that combination therapy was preferred to widen the antibacterial spectrum or to increase the synergistic bactericidal activity of the treatment in severe infections, this representing a confounding factor. The role of combined treatment in the setting of MSSA and MRSA bacteremia, however, appears promising but is yet to be defined \[[@pone.0170236.ref031]\]

Considerable early and late mortality rates were reported in our study (13% and 26%, respectively). Previous studies that analysed risk factors associated with SAB early mortality (e.g. within 2 to 9 days from the onset of the infection) showed mortality rates around 35% \[[@pone.0170236.ref010], [@pone.0170236.ref011]\] \[[@pone.0170236.ref012]\] \[[@pone.0170236.ref026]\]. Hence, early mortality represents a significant timepoint to analyse in SAB.

Our study presents several limitations. First, its retrospective, observational nature can limit the considerations on patient treatments. Second, we considered overall mortality rather than SAB-related mortality. We tried to overcome this bias using two timepoints for mortality, assuming that early mortality could have been more likely associated with SAB. Third, while not specific criteria for requesting an ID consultation have been established and followed, this option could be more likely requested in patients with more severe infections. To minimize the selection bias, we adjusted the data for confounders using multivariate analysis. Furthermore, molecular testing of *S*.*aureus* was not performed, but because of the retrospective nature of our study, this information was not available.

Conclusions {#sec012}
===========

In conclusion, *S*.*aureus* bacteremia represents a serious infection, associated with significant both early and late mortality. Methicillin resistance is associated mostly to nosocomial and health-care associated infections and may be a risk factor for mortality in patients with SAB. Clinicians should be aware of the severity of patients with *S*. *aureus* bacteremia, and infectious disease consultation should be always considered to improve patients' outcomes.
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